220 related articles for article (PubMed ID: 28341731)
1. Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia.
McGinn OJ; Krishnan S; Bourquin JP; Sapra P; Dempsey C; Saha V; Stern PL
Haematologica; 2017 Jun; 102(6):1075-1084. PubMed ID: 28341731
[TBL] [Abstract][Full Text] [Related]
2. Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer.
Wan YL; Sapra P; Bolton J; Chua JX; Durrant LG; Stern PL
Target Oncol; 2019 Aug; 14(4):465-477. PubMed ID: 31332693
[TBL] [Abstract][Full Text] [Related]
3. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.
Sapra P; Damelin M; Dijoseph J; Marquette K; Geles KG; Golas J; Dougher M; Narayanan B; Giannakou A; Khandke K; Dushin R; Ernstoff E; Lucas J; Leal M; Hu G; O'Donnell CJ; Tchistiakova L; Abraham RT; Gerber HP
Mol Cancer Ther; 2013 Jan; 12(1):38-47. PubMed ID: 23223830
[TBL] [Abstract][Full Text] [Related]
4. 5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.
Castro FV; McGinn OJ; Krishnan S; Marinov G; Li J; Rutkowski AJ; Elkord E; Burt DJ; Holland M; Vaghjiani R; Gallego A; Saha V; Stern PL
Leukemia; 2012 Jul; 26(7):1487-98. PubMed ID: 22266911
[TBL] [Abstract][Full Text] [Related]
5. Correction to: Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer.
Wan YL; Sapra P; Bolton J; Chua JX; Durrant LG; Stern PL
Target Oncol; 2019 Dec; 14(6):769. PubMed ID: 31583515
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
7. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
Paul S; Rausch CR; Kantarjian H; Jabbour EJ
Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
[TBL] [Abstract][Full Text] [Related]
8. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
9. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279
[TBL] [Abstract][Full Text] [Related]
10. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
12. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.
Lu H; Kojima K; Battula VL; Korchin B; Shi Y; Chen Y; Spong S; Thomas DA; Kantarjian H; Lock RB; Andreeff M; Konopleva M
Ann Hematol; 2014 Mar; 93(3):485-492. PubMed ID: 24154679
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and Therapeutic Targeting of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
Jeremias I; Schewe DM
Adv Exp Med Biol; 2018; 1100():127-139. PubMed ID: 30411264
[TBL] [Abstract][Full Text] [Related]
14. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
[TBL] [Abstract][Full Text] [Related]
15. The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.
Boghaert ER; Sridharan L; Khandke KM; Armellino D; Ryan MG; Myers K; Harrop R; Kunz A; Hamann PR; Marquette K; Dougher M; DiJoseph JF; Damle NK
Int J Oncol; 2008 Jan; 32(1):221-34. PubMed ID: 18097562
[TBL] [Abstract][Full Text] [Related]
16. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
Hoelzer D
Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.
Ponvilawan B; Vittayawacharin P; Tunsing P; Owattanapanich W
Technol Cancer Res Treat; 2021; 20():15330338211037434. PubMed ID: 34350787
[TBL] [Abstract][Full Text] [Related]
19. An Fc-engineered CD19 antibody eradicates MRD in patient-derived
Schewe DM; Alsadeq A; Sattler C; Lenk L; Vogiatzi F; Cario G; Vieth S; Valerius T; Rosskopf S; Meyersieck F; Alten J; Schrappe M; Gramatzki M; Peipp M; Kellner C
Blood; 2017 Sep; 130(13):1543-1552. PubMed ID: 28698205
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia.
Yadav BD; Samuels AL; Wells JE; Sutton R; Venn NC; Bendak K; Anderson D; Marshall GM; Cole CH; Beesley AH; Kees UR; Lock RB
Oncotarget; 2016 Sep; 7(37):58728-42. PubMed ID: 27623214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
